WO2014018563A3 - Methods for the treatment of cancer - Google Patents

Methods for the treatment of cancer Download PDF

Info

Publication number
WO2014018563A3
WO2014018563A3 PCT/US2013/051737 US2013051737W WO2014018563A3 WO 2014018563 A3 WO2014018563 A3 WO 2014018563A3 US 2013051737 W US2013051737 W US 2013051737W WO 2014018563 A3 WO2014018563 A3 WO 2014018563A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
methods
cancer
cancers
neuroendocrine tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/051737
Other languages
French (fr)
Other versions
WO2014018563A2 (en
Inventor
Julien SAGE
Atul J. Butte
Joel T. DUDLEY
Nadine JAHCHAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of WO2014018563A2 publication Critical patent/WO2014018563A2/en
Publication of WO2014018563A3 publication Critical patent/WO2014018563A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Described herein are methods for the treatment of cancers, particularly neuroendocrine tumors. Also described herein are methods for selecting drug candidates for the treatment of cancers such as neuroendocrine tumors.
PCT/US2013/051737 2012-07-23 2013-07-23 Methods for the treatment of cancer Ceased WO2014018563A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261674810P 2012-07-23 2012-07-23
US61/674,810 2012-07-23

Publications (2)

Publication Number Publication Date
WO2014018563A2 WO2014018563A2 (en) 2014-01-30
WO2014018563A3 true WO2014018563A3 (en) 2014-05-01

Family

ID=49997958

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/051737 Ceased WO2014018563A2 (en) 2012-07-23 2013-07-23 Methods for the treatment of cancer

Country Status (1)

Country Link
WO (1) WO2014018563A2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US10639315B1 (en) 2019-05-21 2020-05-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating Alzheimer's disease
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US10946026B2 (en) 2019-04-12 2021-03-16 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009012109A2 (en) 2007-07-13 2009-01-22 Emory University Cyanine-containing compounds for cancer imaging and treatment
US9675620B2 (en) 2011-07-26 2017-06-13 University Of Southern California MAO inhibitors and their conjugates as therapeutics for the treatment of brain cancer
CN106132437A (en) * 2014-02-07 2016-11-16 南加州大学 MAO inhibitor and conjugate thereof as brain cancer treatment therapeutic agent
US20170304286A1 (en) * 2014-10-24 2017-10-26 Launx Biomedical Co., Ltd. New indication of paroxetine pharmaceutical composition for treating cancer
BR112017015013A2 (en) 2015-01-19 2018-01-23 Belina Pharma Ab antihistamine for use in breast cancer treatment
KR101938036B1 (en) 2015-04-16 2019-01-14 서울대학교산학협력단 Method for inhibiting lung carcinogenesis of both smokers and non-smokers by using antihypertensive drugs
WO2016167605A2 (en) * 2015-04-16 2016-10-20 서울대학교 산학협력단 Method for inhibiting lung cancer of smokers and non-smokers using hypertension medicine
US10946020B2 (en) * 2016-04-06 2021-03-16 University Of Virginia Patent Foundation Compositions and methods for treating cancer
EP3452047B1 (en) * 2016-05-02 2021-04-07 TA Pharma Pty Ltd Compositions comprising estriol and amitriptyline or nortriptyline for the treatment of chronic vulval and perineal pain and symptoms and conditions associated therewith
US20210121475A1 (en) * 2017-06-20 2021-04-29 The Board Of Regents Of The Universy Of Texas System Imipramine compositions and methods of treating cancer
US11357766B2 (en) 2017-11-13 2022-06-14 Texas Tech University System Compositions and methods for treating cancer
US12403222B2 (en) 2018-09-23 2025-09-02 University Of Wollongong Implantable device and a method for implanting said device in a subject
WO2020205458A1 (en) * 2019-03-29 2020-10-08 Washington State University Combination therapy to treat cancer and uses thereof
EP3952840A4 (en) * 2019-04-12 2022-11-23 La Pharma Tech Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF MENTAL BEHAVIOR COGNITIVE DISORDERS
CN110755431B (en) * 2019-11-08 2023-02-28 暨南大学 Application of desloratadine in the preparation of anti-liver cancer drugs
US20230330111A1 (en) * 2020-08-31 2023-10-19 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Active agent combination for treatment of cancer
CN114432446B (en) * 2020-11-05 2023-07-04 南湖实验室 Application of antihistamine in preparation of antitumor drugs
US20220265601A1 (en) * 2021-02-10 2022-08-25 David Alan Heldreth, JR. Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.
US20240307393A1 (en) * 2021-07-06 2024-09-19 National Cancer Center Pharmaceutical composition for cancer prevention or treatment, comprising cdk4/6 inhibitor and tricyclic antidepressant
CN121335713A (en) * 2023-06-17 2026-01-13 香港大学 Cholinergic immunotherapy for the treatment of liver cancer
CN117257782B (en) * 2023-11-07 2024-08-30 广州医科大学 Application of melitracin in reversing Oritinib resistance
CN118649159A (en) * 2024-06-12 2024-09-17 深圳技术大学 Application of doxepin hydrochloride in the preparation of anti-tumor drugs
CN118750506B (en) * 2024-07-15 2025-11-18 杭州市第一人民医院(西湖大学附属杭州市第一人民医院) Application of the combination of vortioxetine and gemcitabine in the preparation of anti-pancreatic cancer drugs

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018402A1 (en) * 1998-09-28 2000-04-06 Merck & Co., Inc. Method for treating androgen-related conditions
WO2002036114A1 (en) * 2000-11-01 2002-05-10 Respiratorius Ab Composition comprising serotonin receptor antagonists, 5 ht-2 and 5 ht-3
US20020193371A1 (en) * 2001-06-01 2002-12-19 Adam Telerman Drugs which can be used in the treatment of cancer
WO2003007925A1 (en) * 2001-07-19 2003-01-30 Isis Innovation Limited Therapeutic strategies for prevention and treatment of alzheimer's disease
WO2007006581A2 (en) * 2005-07-13 2007-01-18 Universitätsklinikum Freiburg Targeting lsd1 for use in identifying and/or scoring prostate cancer and for controlling anrogen receptor-dependent gene expression
WO2007109142A2 (en) * 2006-03-17 2007-09-27 Oregon Health & Science University M3 muscarinic receptor antagonists for treating tumors
US20090005456A1 (en) * 2007-05-31 2009-01-01 Sepracor Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
WO2011050180A1 (en) * 2009-10-21 2011-04-28 Immunogen, Inc. Novel dosing regimen and method of treatment
WO2012106851A1 (en) * 2011-02-12 2012-08-16 安徽三安光电有限公司 Method of cleaving semiconductor wafer or package substrate

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018402A1 (en) * 1998-09-28 2000-04-06 Merck & Co., Inc. Method for treating androgen-related conditions
WO2002036114A1 (en) * 2000-11-01 2002-05-10 Respiratorius Ab Composition comprising serotonin receptor antagonists, 5 ht-2 and 5 ht-3
US20020193371A1 (en) * 2001-06-01 2002-12-19 Adam Telerman Drugs which can be used in the treatment of cancer
WO2003007925A1 (en) * 2001-07-19 2003-01-30 Isis Innovation Limited Therapeutic strategies for prevention and treatment of alzheimer's disease
WO2007006581A2 (en) * 2005-07-13 2007-01-18 Universitätsklinikum Freiburg Targeting lsd1 for use in identifying and/or scoring prostate cancer and for controlling anrogen receptor-dependent gene expression
WO2007109142A2 (en) * 2006-03-17 2007-09-27 Oregon Health & Science University M3 muscarinic receptor antagonists for treating tumors
US20090005456A1 (en) * 2007-05-31 2009-01-01 Sepracor Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
WO2011050180A1 (en) * 2009-10-21 2011-04-28 Immunogen, Inc. Novel dosing regimen and method of treatment
WO2012106851A1 (en) * 2011-02-12 2012-08-16 安徽三安光电有限公司 Method of cleaving semiconductor wafer or package substrate

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116773B2 (en) 2019-04-12 2021-09-14 LA PharmaTech Inc. Method of treating dementia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US12138269B2 (en) 2019-04-12 2024-11-12 LA PharmaTech Inc. Method of treating dementia
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US10946026B2 (en) 2019-04-12 2021-03-16 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US10966989B2 (en) 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US10639316B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Parkinson's disease
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US10639315B1 (en) 2019-05-21 2020-05-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating Alzheimer's disease
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders

Also Published As

Publication number Publication date
WO2014018563A2 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
WO2014018563A3 (en) Methods for the treatment of cancer
IL243788B (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
IL262509A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
EP3092006A4 (en) Targeted therapy for small cell lung cancer
EP3265079A4 (en) Molecular profiling for cancer
EP3033079A4 (en) Methods for the treatment of her2 amplified cancer
EP3027192A4 (en) Methods for the treatment of solid tumors
WO2013056148A3 (en) Scd1 antagonists for treating cancer
EP4276200A3 (en) Fgfr-tacc fusion proteins and methods thereof
MX366804B (en) R-spondin translocations and methods using the same.
HK1202313A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
WO2014160645A3 (en) Neuroendocrine tumors
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
EP3201844A4 (en) Patient-specific immunotherapy for treating heterogeneous tumors
MY174883A (en) Treatment of brain cancer
WO2012103810A1 (en) Certain chemical entities, compositions, and methods
EP3736022A3 (en) Treatment and diagnosis of colon cancer
EP2994155A4 (en) Targeting the egfr-sglt1 interaction for cancer therapy
EP3057593A4 (en) Treatment for pancreatic cancer
EP3088001A4 (en) Therapeutic drug for malignant tumors
EP3089745A4 (en) Compounds, compositions, and methods for the treatment of cancers
WO2012106473A3 (en) Dosing for treatment with anti-egfl7 antibodies
EP3277325A4 (en) Combination immunotherapy for small cell lung cancer
WO2014079931A8 (en) Cd44v6-derived peptides for treating breast cancers
WO2013070933A3 (en) Compositions and methods for the treatment of prostate carcinoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13823823

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13823823

Country of ref document: EP

Kind code of ref document: A2